Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on GABLE HOLDINGS INC. We currently have 3 research reports from 3 professional analysts.
|30Sep16 14:30||RNS||Half-year Report|
|16Sep16 14:50||RNS||Update re: delisting|
|12Sep16 07:30||RNS||Suspension - Gable Holdings Inc.|
|12Sep16 07:00||RNS||NOMAD and Suspension|
|12Sep16 07:00||RNS||Strategic Restructuring and Intention to Delist|
|09Sep16 11:40||RNS||Board Changes|
|31Aug16 12:06||RNS||Directorate Change|
Frequency of research reports
Research reports on
GABLE HOLDINGS INC
GABLE HOLDINGS INC
Approaching the end of the tunnel
06 Oct 15
Gable Holdings is a specialist non-life insurer focussed on writing SME business. It looks for niche areas and for each line it works through a Managing General Agent who deals with customers and claims handling. Having only started in 2006, this has been very successful and it now has 20 lines across Europe. Premium growth has been very strong organically as well as from new lines, with 31% historic growth, a trend we expect to continue. On an underlying basis underwriting results have been good and looking forward we expect combined ratios of around 90%.
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Small Cap Breakfast
21 Mar 17
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march. Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.